Vimarsana
Biggest News Aggregation in the World

Daria Lemann Blumenthal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daria Lemann Blumenthal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daria Lemann Blumenthal Today - Breaking & Trending Today

Alcon to buy Israeli glaucoma treatment co Belkin Vision - Vimarsana News

Alcon to buy Israeli glaucoma treatment co Belkin Vision

The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.

BELKIN Vision Announces FDA Clearance for the Eagle™ Device - Vimarsana News

BELKIN Vision Announces FDA Clearance for the Eagle™ Device

/PRNewswire/ - [BELKIN Vision], an innovator in ophthalmic medical solutions, is pleased to announce that the U.S. Food and Drug Administration (FDA) has...

BELKIN Vision Ltd.: BELKIN Vision's Eagle Receives CE Mark under MDR - Vimarsana News

BELKIN Vision Ltd.: BELKIN Vision's Eagle Receives CE Mark under MDR

Accessible First-Line Contactless Glaucoma Care Now Available in Europe YAVNE, Israel, May 16, 2022 /PRNewswire/ -- BELKIN Vision, the Israel-based medical device company committed to bringing

Israeli Start Up Offers New Treatment For Glaucoma - Vimarsana News

Israeli Start Up Offers New Treatment For Glaucoma

The Direct SLT, invented by Belkin Vision, automates the laser treatment that's currently available

Source: i24news.tv
BELKIN Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Seconds - Vimarsana News

BELKIN Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Seconds

BELKIN Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Seconds YAVNE, Israel, May, 10, 2021 /PRNewswire/ -- BELKIN Laser, the Israel-based start-up bringing a fast, automated and non-invasive glaucoma laser treatment to market announced today that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, non-inferiority, observer masked RCT a total of 192 patients were randomized across two arms, SLT and DSLT. 6-month follow up for primary endpoint is expected in January of 2022 and 12-month follow ...